Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 13/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | MC3R | P41968 | 6/20 | 0.45 |
| ▸ | MC5R | P33032 | 5/20 | 0.45 |
| ▸ | MC1R | Q01726 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968947 | 1.00 | MC4R (0.50) | MC4RPDE4BMC3RMC5RMC1R | |
| SCHEMBL13493029 | 1.00 | MC4R (0.50) | MC4RPDE4BMC3RMC5RMC1R | |
| SCHEMBL4410764 | 0.91 | MC4R (0.49) | MC4RSMN1; SMN2 | |
| SCHEMBL4938875 | 0.91 | MC4R (0.49) | MC4RSMN1; SMN2 | |
| SCHEMBL4414387 | 0.91 | MC4R (0.49) | MC4RSMN1; SMN2 | |
| SCHEMBL3803361 | 0.90 | SMN1; SMN2 (0.48) | MC4RPDE4BTACR1SMN1; SMN2 | |
| SCHEMBL3799557 | 0.90 | SMN1; SMN2 (0.48) | MC4RPDE4BTACR1SMN1; SMN2 | |
| SCHEMBL3798837 | 0.90 | SMN1; SMN2 (0.48) | MC4RPDE4BTACR1SMN1; SMN2 | |
| SCHEMBL18914417 | 0.89 | PDE4B (0.59) | MC4RPDE4BMC3RMC5RMC1R | |
| SCHEMBL13525795 | 0.89 | PDE4B (0.59) | MC4RPDE4BMC3RMC5RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3037412-B1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2020-09-30 | — | — | EP | disclosed |
| US-9868731-B2 | Indole amide compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2018-01-16 | — | — | US | disclosed |
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-07 | — | — | US | disclosed |
| EP-3037412-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
| US-8921394-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2326638-B9 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LTD (GB) | 2013-11-13 | — | — | EP | disclosed |
| US-8569299-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569299-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569299-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2326638-B1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| WO-2008007930-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |
| EP-1716135-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | Pfizer Limited (GB) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077935-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LIMITED (GB) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | MC4R 1120/4885PDE4B 2571/4885MC3R 680/4885 |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | MC4R 4/4885PDE4B 131/4885MC3R 86/4885 |
| US-20050176772-A1 | Pharmaceutically active compounds | MC4R, MC3R, MC5R | MC4R 1/4885PDE4B 270/4885MC3R 2/4885 |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MC4R, MC5R, GPR4 | MC4R 1/4885PDE4B 263/4885MC3R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.